<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2E60EE03-E401-4805-B4A9-DD226392E36D/chart/price-vs-fair-value?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2E60EE03-E401-4805-B4A9-DD226392E36D/chart/price-vs-fair-value"/></p>
<p>TSE:6508 1 年股價與公允價值</p>
<p>探索來自社區的 Meidensha 公允價值並選擇您的觀點</p>
<p>對於 <strong>明電舍株式會社</strong>（TSE:6508）的股東來説，這一週過得不錯，因為公司剛剛發佈了最新的季度業績，股價上漲了 3.6%，達到了 JP¥5,710。整體結果令人信服，收入為 JP¥58 億，法定每股收益為 JP¥408，均符合分析師的預期，顯示出明電舍的執行與預期一致。盈利是投資者關注的重要時刻，因為他們可以跟蹤公司的表現，查看分析師對明年的預測，並觀察對公司的情緒是否發生變化。讀者會高興地知道，我們匯總了最新的法定預測，以查看分析師在最新結果後是否改變了對明電舍的看法。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/874354-earnings-and-revenue-growth-1-dark-2/1754354135812?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/874354-earnings-and-revenue-growth-1-dark-2/1754354135812"/></p>
<p>TSE:65082025 年 8 月 5 日的收益和收入增長</p>
<p>考慮到最新的結果，明電舍五位分析師的共識預測是 2026 年收入為 JP¥328.5 億。這反映出與過去 12 個月相比，收入有令人滿意的 7.9% 的增長。法定每股收益預計在同一時期下降 6.5%，降至 JP¥370。在這份盈利報告之前，分析師曾預測 2026 年收入為 JP¥328.6 億，每股收益（EPS）為 JP¥363。共識分析師似乎沒有在這些結果中看到任何會改變他們對業務看法的因素，因為他們的預測沒有重大變化。</p>
<p>查看我們對明電舍的最新分析</p>
<p>收入或收益預測以及 JP¥6,160 的價格目標沒有變化，這表明公司在最近的結果中達到了預期。共識價格目標只是各個分析師目標的平均值，因此——查看基礎估計的範圍可能會很有幫助。最樂觀的明電舍分析師的價格目標為每股 JP¥7,200，而最悲觀的則為 JP¥5,000。正如您所見，分析師對該股票的未來並不完全一致，但估計範圍仍然相對狹窄，這可能表明結果並非完全不可預測。</p>
<p>現在從更大的視角來看，我們可以通過將這些預測與過去的表現和行業增長估計進行比較來理解這些預測。分析師們顯然預計明電舍的增長將加速，預計到 2026 年底年均增長 11%，與過去五年年均增長 4.9% 相比表現良好。與同一行業的其他公司相比，後者預計年均收入增長 4.6%。顯然，儘管增長前景比近期更為光明，但分析師們也預計明電舍的增長速度將快於更廣泛的行業。</p>
<h2>結論</h2>
<p>最明顯的結論是，最近業務前景沒有重大變化，分析師們保持了他們的收益預測，與之前的估計一致。令人高興的是，收入預測沒有重大變化，業務仍然預計將比更廣泛的行業增長得更快。共識價格目標沒有實質性變化，這表明業務的內在價值在最新估計中沒有發生重大變化。</p>
<p>考慮到這一點，我們仍然認為，業務的長期發展軌跡對投資者來説更為重要。我們有來自多位明電舍分析師的預測，直到 2028 年，您可以在我們的平台上免費查看。</p>
<p>不過，您應該始終考慮風險。舉個例子，我們發現了 <strong>明電舍的 1 個警告信號</strong>，您應該注意。</p>

6508

<p>美電社（TSE:6508）公佈了第一季度業績，收入為 580 億日元，每股收益為 408 日元，符合分析師預期。股價上漲 3.6%，達到 5,710 日元。分析師預測 2026 年收入為 3,285 億日元，增長 7.9%，但預計每股收益將下降 6.5%，降至 370 日元。共識目標價維持在 6,160 日元，估計範圍在 5,000 日元至 7,200 日元之間。總體來看，分析師認為美電社的增長速度將快於行業，預計到 2026 年的年增長率為 11%</p>

<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2E60EE03-E401-4805-B4A9-DD226392E36D/chart/price-vs-fair-value" alt="" original-src="https://images.simplywall.st/company/2E60EE03-E401-4805-B4A9-DD226392E36D/chart/price-vs-fair-value"/></p>
<p>TSE:6508 1 Year Share Price vs Fair Value</p>
<div class="lb-trans"><p>TSE:6508 1 年股價與公允價值</p>
</div><p>Explore Meidensha's Fair Values from the Community and select yours</p>
<div class="lb-trans"><p>探索來自社區的 Meidensha 公允價值並選擇您的觀點</p>
</div><p>It's been a good week for <strong>Meidensha Corporation</strong> (TSE:6508) shareholders, because the company has just released its latest quarterly results, and the shares gained 3.6% to JP¥5,710. It was a credible result overall, with revenues of JP¥58b and statutory earnings per share of JP¥408 both in line with analyst estimates, showing that Meidensha is executing in line with expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Meidensha after the latest results.</p>
<div class="lb-trans"><p>對於 <strong>明電舍株式會社</strong>（TSE:6508）的股東來説，這一週過得不錯，因為公司剛剛發佈了最新的季度業績，股價上漲了 3.6%，達到了 JP¥5,710。整體結果令人信服，收入為 JP¥58 億，法定每股收益為 JP¥408，均符合分析師的預期，顯示出明電舍的執行與預期一致。盈利是投資者關注的重要時刻，因為他們可以跟蹤公司的表現，查看分析師對明年的預測，並觀察對公司的情緒是否發生變化。讀者會高興地知道，我們匯總了最新的法定預測，以查看分析師在最新結果後是否改變了對明電舍的看法。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/874354-earnings-and-revenue-growth-1-dark-2/1754354135812" alt="" original-src="https://images.simplywall.st/asset/chart/874354-earnings-and-revenue-growth-1-dark-2/1754354135812"/></p>
<p>TSE:6508 Earnings and Revenue Growth August 5th 2025</p>
<div class="lb-trans"><p>TSE:65082025 年 8 月 5 日的收益和收入增長</p>
</div><p>Taking into account the latest results, the consensus forecast from Meidensha's five analysts is for revenues of JP¥328.5b in 2026. This reflects a satisfactory 7.9% improvement in revenue compared to the last 12 months. Statutory earnings per share are expected to decrease 6.5% to JP¥370 in the same period. Before this earnings report, the analysts had been forecasting revenues of JP¥328.6b and earnings per share (EPS) of JP¥363 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.</p>
<div class="lb-trans"><p>考慮到最新的結果，明電舍五位分析師的共識預測是 2026 年收入為 JP¥328.5 億。這反映出與過去 12 個月相比，收入有令人滿意的 7.9% 的增長。法定每股收益預計在同一時期下降 6.5%，降至 JP¥370。在這份盈利報告之前，分析師曾預測 2026 年收入為 JP¥328.6 億，每股收益（EPS）為 JP¥363。共識分析師似乎沒有在這些結果中看到任何會改變他們對業務看法的因素，因為他們的預測沒有重大變化。</p>
</div><p>Check out our latest analysis for Meidensha</p>
<div class="lb-trans"><p>查看我們對明電舍的最新分析</p>
</div><p>There were no changes to revenue or earnings estimates or the price target of JP¥6,160, suggesting that the company has met expectations in its recent result. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Meidensha analyst has a price target of JP¥7,200 per share, while the most pessimistic values it at JP¥5,000. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.</p>
<div class="lb-trans"><p>收入或收益預測以及 JP¥6,160 的價格目標沒有變化，這表明公司在最近的結果中達到了預期。共識價格目標只是各個分析師目標的平均值，因此——查看基礎估計的範圍可能會很有幫助。最樂觀的明電舍分析師的價格目標為每股 JP¥7,200，而最悲觀的則為 JP¥5,000。正如您所見，分析師對該股票的未來並不完全一致，但估計範圍仍然相對狹窄，這可能表明結果並非完全不可預測。</p>
</div><p>Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The analysts are definitely expecting Meidensha's growth to accelerate, with the forecast 11% annualised growth to the end of 2026 ranking favourably alongside historical growth of 4.9% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 4.6% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Meidensha to grow faster than the wider industry.</p>
<div class="lb-trans"><p>現在從更大的視角來看，我們可以通過將這些預測與過去的表現和行業增長估計進行比較來理解這些預測。分析師們顯然預計明電舍的增長將加速，預計到 2026 年底年均增長 11%，與過去五年年均增長 4.9% 相比表現良好。與同一行業的其他公司相比，後者預計年均收入增長 4.6%。顯然，儘管增長前景比近期更為光明，但分析師們也預計明電舍的增長速度將快於更廣泛的行業。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>結論</h2>
</div><p>The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.</p>
<div class="lb-trans"><p>最明顯的結論是，最近業務前景沒有重大變化，分析師們保持了他們的收益預測，與之前的估計一致。令人高興的是，收入預測沒有重大變化，業務仍然預計將比更廣泛的行業增長得更快。共識價格目標沒有實質性變化，這表明業務的內在價值在最新估計中沒有發生重大變化。</p>
</div><p>Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Meidensha analysts - going out to 2028, and you can see them free on our platform here.</p>
<div class="lb-trans"><p>考慮到這一點，我們仍然認為，業務的長期發展軌跡對投資者來説更為重要。我們有來自多位明電舍分析師的預測，直到 2028 年，您可以在我們的平台上免費查看。</p>
</div><p>You should always think about risks though. Case in point, we've spotted <strong>1 warning sign for Meidensha</strong> you should be aware of.</p>
<div class="lb-trans"><p>不過，您應該始終考慮風險。舉個例子，我們發現了 <strong>明電舍的 1 個警告信號</strong>，您應該注意。</p>
</div>

明電舍株式會社（TSE:6508）第一季度業績：分析師對今年的預測如下